Table 3.

Secondary Objectives of the APEX COPD Registry Initiative

Improve quality of care, and primary care patient outcomes through structured COPD support and increased understanding of COPD management
Understand the clinical phenotypes of COPD that predict response to or appropriateness of inhaled treatments
Understand the current burden and minimize side effects of steroid exposure through use of appropriate treatments
Support the development of effective and efficient diagnostic routines and therapeutic principles
Assess the level of classification differences as defined by comparing clinician-diagnosed COPD at baseline against established guidelines’ diagnostic criteria
Describe disease management patterns such as treatment changes over time (eg, step up, step down, and switches), as well as the reasons for changes and the effect of these changes on disease progression
Assess the impact of inhaler technique, inhaler type and lung function on disease management and severity (eg, exacerbations and CAT scores)
Describe factors associated with treatment choice at baseline and describe disease progression
Describe risk factors (eg, age, sex, smoking, BMI, occupation, family history, presence of comorbidities, socioeconomic status, quality of care, lung function, exacerbations) associated with disease progression, PROs, and healthcare utilization
Assess the occurrence of exacerbations and other conditions, including URTIs and seasonal variations
Assess biomarker data and estimate their predictive value for disease diagnosis, pheno- and endo-type characterization, response to treatment and disease progression
Identify patients who may be eligible for participation in future research studies
  • APEX, Advancing the Patient Experience; BMI, body mass index; CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; PRI/PRO, patient-reported information & outcomes; URTI, upper respiratory tract infection.